Search Results - haemophilus

3 Results Sort By:
Real-Time PCR Assay for Specific Detection of Haemophilus influenzae Serotypes A and B
Haemophilus influenzae is responsible for life-threatening respiratory infections including meningitis. This assay allows for the qualitative detection of the bacterial meningitis pathogen H. influenzae serotype A (Hia) and serotype B (Hib) in fluid samples, without detecting any of the other serotypes of H. influenzae. This invention is capable of...
Published: 10/28/2024   |   Inventor(s): Xin Wang, Cynthia Hatcher, Raydel Anderson, Mary Theodore, Leonard Mayer, Jennifer Thomas
Keywords(s): CDC Docket Import, CDC Docket Import CDC Prosecuting, DA3XXX, DAXXXX, Detection, DXXXXX, HAEMOPHILUS, INFLUENZAE, OID-NCIRD-DBD, SELECTIVE
Category(s): Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, Application > Diagnostics
Moraxella Catarrhalis Lipooligosaccharide Based Conjugate Vaccines for the Prevention of Otitis Media and Respiratory Infections
Moraxella catarrhalis is one of the three leading causative agents of otitis media in children. This is due in part to the current immunizations of children with Streptococcus pneumoniae polysaccharide and conjugate vaccines to prevent otitis media. The proportion of otitis media caused by pneumococcal strains covered by the vaccines have decreased...
Published: 10/28/2024   |   Inventor(s): John Robbins, Xin-xing Gu
Keywords(s): BBXXXX, BCXXXX, BRANHAMELLA, CATARHALIS, Catarrhalis, DC4XXX, DCXXXX, DETOXIFIED, DXXXXX, HAEMOPHILUS, Haemophilus influenzae, Humans, Immunization, INFECTIONS, INFLUENZAE, Intranasal, Lipooligosaccharide, LIPOOLIGOSACCHARIDE-BASED, MORAXELLA, NONTYPEABLE, OTITIS MEDIA, Patent Category - Biotechnology, Prevention, Tetanus, UAXXXX, Vaccine, With...
Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Infectious Disease, Application > Vaccines, TherapeuticArea > Rare / Neglected Diseases
Peptide Mimotope Candidates for Otitis Media Vaccine
This technology describes peptide mimotopes of lipooligosaccharides (LOS) from nontypeable Haemophilus influenzae (NTHi) and Moraxella catarrhalis that are suitable for developing novel vaccines against the respective pathogens, for which there are currently no licensed vaccines. The mimotopes not only immunologically mimic LOSs from NTHi and M. catarrhalis...
Published: 10/28/2024   |   Inventor(s): Xin-xing Gu
Keywords(s): BCXXXX, CANDIDATES, DC5BXX, DC5XXX, DCXXXX, Development, DXXXXX, H. Influenzae, HAEMOPHILUS, HAEMOPHILUS INFLUENZ, Haemophilus influenzae, INFLUENZA, Lipoligosaccharide, MIMICING AGENT, Minotopes, NONTYPEABLE, OTITIS MEDIA, Peptide, Peptides, UAXXXX, Vaccine
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Vaccines, TherapeuticArea > Rare / Neglected Diseases, TherapeuticArea > Infectious Disease